Friday, July 10, 2026

Patent intelligence · US

US 12128044

Fused tricyclic compounds and uses thereof in medicine

granted A61KA61K31/427A61K31/429A61K31/5025
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 121
Patent details — US 12128044
Jurisdiction
US
Status
granted
Grant date
Oct 29, 2024
Expiration
Oct 24, 2044
Claims
21
CPC classes
A61K, A61K31/427, A61K31/429, A61K31/5025
View on Google Patents ↗

Quick answer

US 12128044 (Fused tricyclic compounds and uses thereof in medicine) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
21
CPC classes
A61K, A61K31/427, A61K31/429, A61K31/5025, A61K31/513, A61K31/52

More from SUNSHINE LAKE PHARMA CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 12128044?

US 12128044 (Fused tricyclic compounds and uses thereof in medicine) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12128044?

SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 12128044 expire?

Our index shows an expiration date of Oct 24, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.